• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book Apps
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Topics » General Psychiatry » Files

General Psychiatry

TETRABENAZINE (Xenazine) Fact Sheet [G]

November 29, 2023

Tetrabenazine was the original VMAT inhibitor brought to market and approved for the treatment of Huntington’s disease. It’s an off-label alternative to deutetrabenazine and valbenazine for treating tardive dyskinesia (TD). Although it’s much less expensive, it requires more frequent dosing and may have a higher likelihood of causing depression. From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

BUPROPION (Wellbutrin others) Fact Sheet [G]

November 29, 2023

May be particularly useful for individuals whose depression is associated with fatigue and poor concentration. Absence of sexual side effects and weight gain make this an appealing option for many depressed patients. Although not effective for anxiety disorders, it is effective for the anxiety that often accompanies depression. The seizure risk is not a concern for most patients when dosed appropriately From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

FLIBANSERIN (Addyi) Fact Sheet

November 29, 2023

Flibanserin, marketed as the “pink Viagra,” is mildly effective for enhancing sexual desire, but with potentially significant side effects and precautions regarding alcohol use around the time of administration. From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

METFORMIN (Glucophage, Glumetza, Riomet) Fact Sheet [G]

November 29, 2023

Metformin is a medication for type 2 diabetes that increases insulin sensitivity and decreases appetite. It’s somewhat effective for antipsychotic-induced weight gain (average of 3 kg weight loss) and might work better if started prophylactically as a way to prevent excessive weight gain in the first place. It’s quite safe and well tolerated (with some GI side effects) and is becoming a standard add-on treatment in patients taking clozapine or olanzapine. From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

MIXED AMPHETAMINE SALTS (Adderall, Adderall XR, Mydayis) Fact Sheet [G]

November 29, 2023

Adderall contains 75% dextroamphetamine and 25% levoamphetamine. This ratio of amphetamine isomers is effective but is probably the most abused and diverted of all prescription stimulants. From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

DESVENLAFAXINE (Pristiq) Fact Sheet [G]

November 29, 2023

Desvenlafaxine is the active metabolite of venlafaxine, and it has some minor advantages in terms of drug interactions, ease of dosing, and longer half-life. One disadvantage is lack of FDA approval for anxiety disorders. At least for depression, since desvenlafaxine is now available in a low-cost generic version, some clinicians prefer it over venlafaxine XR. From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

METHYLPHENIDATE TRANSDERMAL (Daytrana) Fact Sheet [G]

November 29, 2023

Daytrana is helpful for kids who, for whatever reason, cannot use any of the wide variety of oral stimulant preparations. Otherwise, we don’t recommend it due to high cost, lag time for onset of effect, and the side effect of rash, which is pretty common and unpleasant. From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

NEFAZODONE (Serzone) Fact Sheet [G]

November 29, 2023

Nefazodone was once popular due to the lack of sexual side effects, but is now rarely used due to rare hepatic effects. From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

LAMOTRIGINE (Lamictal Lamictal XR Subvenite) Fact Sheet [G]

November 29, 2023

Bottom Line: Lamotrigine is a good choice for maintenance treatment of bipolar disorder, especially to prevent depressive episodes. It has a good side effect profile. Its main disadvantage is the very slow titration schedule recommended to decrease the risk of Stevens-Johnson syndrome—as well as its ineffectiveness in the treatment of manic episodes. From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

Orthostatic Hypotension (Postural Hypotension)

November 29, 2023

Orthostatic hypotension (OH) is caused by blood pooling in the lower extremities when people stand up, causing less blood flow to the brain and consequent dizziness. Usually caused by medications that block the alpha-1 receptors, which are responsible for telling the body to constrict blood vessels (and maintain blood pressure) after standing up. Patients will report feeling faint when they get up, and occasionally a sense of the room spinning (vertigo). From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

Previous 1 2 … 16 17 18 19 20 21 22 23 24 … 29 30 Next
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • HospPsychiatry_Spiral_Binding_Sm.png

    Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

    This comprehensive guide is designed to be a valuable resource for professionals working in...
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2639254965.jpg
    General Psychiatry

    Psychopharm Secrets: Starting Meds

    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.